Viking Therapeutics faces intensified pressure as Pfizer opts to acquire Metsera, dashing hopes for a potential buyout amid its promising development of weight loss drug VK2735. Despite strong buy recommendations from analysts, Viking's shares are down 5.78% and carry a Zacks Rank of 'Sell,' with projections of growing losses ahead. With fierce competition from industry giants Eli Lilly and Novo Nordisk, and the weight loss market expanding to nearly $100 billion by 2030, Viking must navigate significant challenges to enhance its market position.
“Viking Therapeutics · has an average brokerage recommendation · 1.32 · on a scale of 1 to 5”
“the average brokerage recommendation · is calculated based on · the recommendations made by 19 brokerage firms”
“16 recommendations · are · Strong Buy · representing 84.2% of all recommendations”
“brokerage recommendations · have little to no success · guiding investors · to choose stocks with the most potential for price appreciation”
“brokerage firms · assign · five 'Strong Buy' recommendations for every 'Strong Sell' recommendation”
“Zacks Rank · categorizes stocks · into five groups · ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell)”
“the ABR · is not necessarily up-to-date”
“the Zacks Rank · is designed to harness · the power of earnings estimate revisions”
“the Zacks Consensus Estimate for the current year · has declined · 2.4% · over the past month”
“Viking Therapeutics · has a Zacks Rank · #4 · (Sell)”
“Viking Therapeutics, Inc. (VKTX) · closed at · $25.09 · -5.78% move from the prior day”
“the stock's change · was less than · the S&P 500's daily loss · 0.5%”
.svg&width=160)
